Vivaldi Capital Management LP Editas Medicine, Inc. Transaction History

Vivaldi Capital Management LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2018 Feb 13, 2019	SELL	$18.19 - $31.79 $192,268 - $336,020	-10,570 Closed	0 $0
Q1 2018 May 08, 2018	BUY	$29.84 - $44.08 $89,520 - $132,240	3,000 Added 39.63%	10,570 $350,000
Q4 2017 Feb 14, 2018	BUY	$21.89 - $31.34 $165,707 - $237,243	7,570	7,570 $233,000

243

69.3M

564K

428K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $320M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Vivaldi Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Vivaldi Capital Management LP with notifications on news.